REG - Genflow Biosciences - Total Voting Rights

Genflow BiosciencesAnnouncement

30/04/2024 07:15

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240430:nRSd2788Ma&default-theme=true

RNS Number : 2788M  Genflow Biosciences PLC  30 April 2024

THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO
CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION
(EU) NO. 596/2014 AS IT FORMS PART OF UK DOMESTIC LAW PURSUANT TO THE EUROPEAN
UNION (WITHDRAWAL) ACT 2018, AS AMENDED. UPON THE PUBLICATION OF THIS
ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS
CONSIDERED TO BE IN THE PUBLIC DOMAIN.

 

30 April 2024

 

Genflow Biosciences Plc

 

Total Voting Rights

 

Genflow Biosciences Plc (LSE:GENF) (OTCQB:GENFF) ("Genflow" or "the Company"),
an emerging leader in the field of longevity research, focused on developing
therapeutic solutions for the prevention of age-related diseases, announces
that the total issued share capital of the Company as at 30 April 2024
consists of 349,706,618 Ordinary Shares none of which are held in treasury.
Therefore, the total number of voting rights in the Company is 349,706,618.

 

The figure of 349,706,618 Ordinary Shares may be used by shareholders of the
Company as the denominator for the calculations by which they will determine
if they are required to notify their investment in, or a change in their
interest in, the share capital of the Company under the Financial Conduct
Authority's Disclosure Guidance and Transparency Rules.

 

Contacts

 Genflow Biosciences   Harbor Access
 Dr Eric Leire, CEO    Jonathan Paterson, Investor Relations
 +32-477-495-881       +1 475 477 9401
                       Jonathan.Paterson@Harbor-access.com

 

 Joint Corporate Brokers
 Clear Capital Markets          Capital Plus Partners Ltd
 Bob Roberts, +44 203 869 6080  Dominic Berger, +44 203 821 6167
                                Keith Swann, +44 0203 821 6169
                                Jon Critchley, +44 0203 821 6168

About Genflow Biosciences

 

Founded in 2020, Genflow Biosciences Plc. (LSE:GENF) (OTCQB:GENFF), a
biotechnology company headquartered in the UK with R&D facilities in
Belgium, is pioneering gene therapies to decelerate the aging process, with
the goal of promoting longer and healthier lives while mitigating the
financial, emotional, and social impacts of a fast-growing aging global
population. Genflow's lead compound, GF-1002, works through the delivery of a
centenarian variant of the SIRT6 gene which has yielded promising preclinical
results. Scheduled to begin in 2025, Genflow's clinical trial aims to explore
the potential benefits of GF-1002 in treating non-alcoholic steatohepatitis
(NASH), the most prevalent chronic liver disease for which there is no
effective treatments. Please visit www.genflowbio.com
(http://www.genflowbio.com)  and follow the Company on LinkedIn and
Twitter/X.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  TVRPPURCCUPCGCQ